Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer
NCT04487587Phase 2Active, not recruiting
- Start
- Oct 2018
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib, olaparib in Cervical Cancer (CC). Started Oct 2018; status: active, not recruiting.
02
Drugs
cediranibolaparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04487587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487587.